| |
| |
|
| Insider
Information: |
Tessier-Lavigne Marc |
| Relationship: |
Director |
| City: |
So San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
2,228,119 |
|
|
Indirect Shares
|
236,869 |
|
|
| Direct
Value |
$40,029,853 |
|
|
|
Indirect Value
|
$4,337,071 |
|
|
| Total
Shares |
2,464,988 |
|
|
| Total
Value |
$44,366,924 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
9
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 42.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Pfizer Inc |
PFE |
Director |
2011-12-12 |
104 |
|
0 |
Premium* |
|
|
Regeneron Pharmaceuticals Inc |
REGN |
Director |
2023-01-03 |
2,434 |
2013-05-06 |
0 |
Premium* |
|
|
Agios Pharmaceuticals Inc |
AGIO |
Director |
2013-07-24 |
101,009 |
|
0 |
Premium* |
|
|
Juno Therapeutics, Inc. |
JUNO |
Director |
2014-12-23 |
250,000 |
|
0 |
Premium* |
|
|
Denali Therapeutics Inc. |
DNLI |
Director |
2023-06-01 |
1,874,572 |
2023-06-01 |
236,869 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
65 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PFE |
Pfizer Inc |
Director |
– • – |
2011-12-12 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
104 |
|
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2013-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
45,454 |
|
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2014-12-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
75,000 |
|
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
175,000 |
250,000 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
3,139,043 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2019-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
323 |
1,510 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
320 |
1,830 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
248 |
2,078 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,074 |
2,544,370 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-10-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
300,000 |
100,000 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-10-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
300,000 |
2,244,370 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
2,269 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
2,030,356 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
165 |
2,434 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,216 |
1,874,572 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2014-08-26 |
4 |
D |
$351.62 |
$70,324 |
D/D |
(200) |
1,187 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2014-08-26 |
4 |
OE |
$50.91 |
$70,612 |
D/D |
1,387 |
1,387 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2014-08-27 |
4 |
OE |
$50.91 |
$152,730 |
D/D |
3,000 |
4,187 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2015-02-26 |
4 |
OE |
$50.91 |
$152,730 |
D/D |
3,000 |
4,187 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-05-03 |
4 |
AS |
$60.08 |
$194,589 |
D/D |
(3,237) |
2,589,059 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-11-01 |
4 |
AS |
$30.20 |
$264,190 |
D/D |
(8,748) |
1,901,608 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2015-08-05 |
4 |
OE |
$57.11 |
$285,550 |
D/D |
5,000 |
6,187 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-11-02 |
4 |
AS |
$30.33 |
$341,273 |
D/D |
(11,252) |
1,890,356 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-06-23 |
4 |
D |
$31.10 |
$412,076 |
D/D |
(13,250) |
2,017,106 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-12-28 |
4 |
S |
$44.37 |
$487,219 |
I/I |
(10,980) |
96,354 |
0 |
% |
|
65 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
